AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.

Award Information

Agency: Department of Health and Human Services

Branch: N/A

Contract: N/A

Agency Tracking Number: 3009

Amount: $49,593.00

Phase: Phase I

Program: SBIR

Solicitation Topic Code: N/A

Solicitation Number: N/A

Timeline

Solicitation Year: N/A

Award Year: 1985

Award Start Date (Proposal Award Date): N/A

Award End Date (Contract End Date): N/A

Small Business Information

American Biotechnology Co

7658 Standish Place, Suite 107

Rockville, MD 20855

United States

DUNS: N/A

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

Principal Investigator

Name: MICHAEL W. BASELER
Title: PRINCIPAL INVESTIGATOR
Phone: (301) 294-9553

Business Contact

Phone: () -

Research Institution

N/A

Abstract

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.THIS PROJECT INVOLVES DETERMINING THE ABILITY OF A NEW CLASS OF SYNTHETIC BIOLOGICAL RESPONSE MODIFIERS (BRM) KNOWN AS METHYLFURYLBUTYROLACTONES (MFBL) TO AUGMENT THE PRODUCTION OF LYMPHOKINES (IL-2, B-CELL GROWTH FACTOR, AND IMMUNE INTERFERON) AND MONOKINES (IL-1, PROSTAGLANDINS, AND CYTOLYTIC FACTOR). OUR LABORATORY HAS DETERMINED THAT THE MFBLS ARE POTENT IMMUNOSTIMULATORY COMPOUNDS. MFBLS ARE CAPABLE OF INCREASING THE FOLLOWING IMMUNE FUNCTIONS: 2.PRIMARY AND SECONDARY ANTIBODY PRODUCTION 3.PHAGOCYTOSIS BY BOTH MACROPHAGES AND PMNS. IT IS KNOWN THAT THE ABOVE MENTIONED IMMUNE FUNCTIONS ARE REGULATED IN SOME WAY BY LYMPHOKINES AND/OR MONOKINES. THEREFORE, WE PLAN TO INVESTIGATE THE POSSIBILITY THAT MFBLS ENHANCE THESE IMMUNE FUNCTIONS BY STIMULATING AN INCREASED PRODUCTION OF LYMPHOKINES AND/OR MONOKINES. THIS HYPOTHESIS WILL BE TESTED BOTH IN VIVO AND IN VITRO USING ESTABLISHED MURINE LYMPHOKINE AND MONOKINE ASSAY SYSTEMS.

* Information listed above is at the time of submission. *

You are here

AND ITS POTENTIAL APPLICATION TO HUMAN HYBRIDOMA TECHNOLOGY.